Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

12.14 -0.52 (-4.12%)
Streaming Delayed Price Updated: 1:33 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Mind Medicine Analyst Cites Strong Phase 3 Pipeline For Anxiety, Depression
Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid cash position. 
Via Benzinga
The Insider Report: Panic Never Pays
 
Via Benzinga
If You'd Invested $1,000 in Mind Medicine (MNMD) Stock 5 Years Ago, Here's How Much You'd Have Today
Mind Medicine stock hasn't beaten the market over the last five years, but what comes next? 
Via The Motley Fool
MindMed (MNMD) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings Initial Public Offering
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Why Mind Medicine Stock Is Skyrocketing Today
Via The Motley Fool
Why Mind Medicine Stock Is Soaring Today
Via The Motley Fool
MindMed Reports Strong Q2 2025 Results
Via The Motley Fool
1 Reason to Buy MindMed (MNMD)
The U.S. public and the nation's politicians seem to be coming around to the idea of reforming psychedelic drug laws. Looser restrictions on research would help this company. 
Via The Motley Fool
Topics Cannabis Law Enforcement
MindMed (MNMD) Q2 Net Loss Jumps 625%
Via The Motley Fool
Topics Intellectual Property
Why Mind Medicine Gave Investors a Powerful Buzz in May
Via The Motley Fool
Topics Law Enforcement
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Psychedelics litigator Matthew Zorn joins HHS under RFK Jr. to lead policy. What it means for CMPS, MNMD, CYBN, PSIL & more. 
Via Benzinga
Topics Government
Why Mind Medicine Stock Vaulted More Than 8% Higher Today
Via The Motley Fool
Let's uncover which stocks are experiencing notable gaps during today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday. 
Via Chartmill
Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Gap To Rally Over 69%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
Mind Medicine's Net Losses Swell In Q4, But Retail Finds At Least 3 Reasons To Stay Bullish
The psychedelics treatment developer reported a net loss of $34.7 million for the quarter ended Dec. 31, 2024, widening from a $23.8 million loss a year earlier. 
Via Stocktwits
Warren Buffett's State of the Market
Berkshire's cash hoard is approaching "Dr. Evil" levels. 
Via The Motley Fool
Mind Medicine Getting An 'RFK Bump'? Retail Gets More Bullish As Stock Heads For Best Day In Over 10 Months
Kennedy has previously advocated for decriminalizing psychedelics for therapeutic use, citing his son’s positive experience with the hallucinogenic brew ayahuasca. 
Via Stocktwits
RFK Jr. Confirmation Looms. How Kennedy Could 'Go Wild' On Health Care.
The Senate will vote Thursday on whether to put RFK Jr. in charge of health. It's unclear how he will impact biotech stocks. 
Via Investor's Business Daily
Earnings Scheduled For March 6, 2025
 
Via Benzinga
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms. 
Via Stocktwits
This Westlake Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Is Your Mind Ready to Consider Investing in Psychedelics Stocks?
Don't jump in without doing some research first. 
Via The Motley Fool
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
The psychedelic compound-based drug market is expected to triple over the next few years, creating many winning stocks in the years to come. 
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
While the psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come, the stocks of the companies involved are... 
Via Talk Markets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
The psychedelic compound-based drug market is expected to triple over the next few years which should create many winning stocks in the years to come and, to monitor their progress we present a... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.